[{"id":"164a11b6-0a88-4e66-b764-a14af3e3880e","acronym":"NCI-2018-01054","url":"https://clinicaltrials.gov/study/NCT03360721","created_at":"2021-01-18T16:35:16.869Z","updated_at":"2025-02-25T12:26:48.752Z","phase":"Phase 2","brief_title":"Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT03360721 - NCI-2018-01054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" AR overexpression • AR expression • AR-V7 expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR overexpression • AR expression • AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide • Yonsa (abiraterone acetate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 03/06/2018","start_date":" 03/06/2018","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-24"}]